D.E. Shaw & Co
RNAC icon

D.E. Shaw & Co’s Cartesian Therapeutics RNAC Stock Holding History

D.E. Shaw & Co’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,379
Closed -$323K – 4979
2021
Q1 		$323K Sell
2,379
-4,087
-63% -$507K ﹤0.01% 3681
2020
Q4 		$588K Buy
+6,466
New +$561K ﹤0.01% 3312
2020
Q3 		– Sell
-4,196
Closed -$357K – 4107
2020
Q2 		$357K Buy
+4,196
New +$380K ﹤0.01% 3553
2019
Q2 		– Sell
-1,022
Closed -$73K – 3831
2019
Q1 		$73K Buy
+1,022
New +$64.8K ﹤0.01% 3501
2017
Q4 		– Sell
-409
Closed -$224K – 3715
2017
Q3 		$224K Buy
+409
New +$218K ﹤0.01% 3260

Other funds holding RNAC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

D.E. Shaw & Co's RNAC Position: Q2 2021 in Review

D.E. Shaw & Co sold out of Cartesian Therapeutics (RNAC) in Q2 2021, closing a stake of 2,379 shares — an estimated $323K sold.

D.E. Shaw & Co first reported a position in RNAC in Q3 2017 and held it in 5 quarters. The position peaked at $588K in Q4 2020. 101 funds tracked by Wall St. Rank hold RNAC as of Q2 2021.

  • D.E. Shaw & Co reported no remaining Cartesian Therapeutics position as of Q2 2021 after selling out during the quarter.
  • D.E. Shaw & Co sold 2,379 Cartesian Therapeutics shares in Q2 2021, an estimated $323K.
  • D.E. Shaw & Co first reported a position in Cartesian Therapeutics in Q3 2017 and held it in 5 quarters.
  • D.E. Shaw & Co's Cartesian Therapeutics position peaked at $588K in Q4 2020.
  • 101 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2021.

Based on D.E. Shaw & Co's 13F filing for Q2 2021, filed 16 Aug 2021.